Commentary: Problems with increasing the use of generic drugs in Spain
Comentario: Los medicamentos genéricos y algunos de los problemas para su implantación en España
a Family Physician and Specialist in Clinical Pharmacology. Co-director, Master´s Program in Primary Health Care and Associate Professor, Autonomous University of Barcelona. Badia del Vallès Primary Care Center, Barcelona, Spain.
b Specialist in Family and Community Medicine, Ripollet Primary Care Center, Barcelona, Spain.
Read
3985
Timeswas read the article
847
Total PDF
3138
Total HTML
Share statistics
array:20 [ "pii" => "13038749" "issn" => "02126567" "estado" => "S300" "fechaPublicacion" => "2002-10-15" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Aten Primaria. 2002;30:348-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1993 "formatos" => array:3 [ "EPUB" => 61 "HTML" => 1621 "PDF" => 311 ] ] "itemSiguiente" => array:15 [ "pii" => "13038155" "issn" => "02126567" "estado" => "S300" "fechaPublicacion" => "2002-10-15" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Aten Primaria. 2002;30:350-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5184 "formatos" => array:3 [ "EPUB" => 51 "HTML" => 4546 "PDF" => 587 ] ] "es" => array:11 [ "idiomaDefecto" => true "titulo" => "Abordaje de la osteoporosis en la atención primaria en España (estudio ABOPAP-2000)" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "350" "paginaFinal" => "356" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Diagnosing osteoporosis in primary care in Spain (ABOPAP 2000 study)" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R Aragonès Forès, P Orozco López, Grupo de Osteoporosis de la Societat Catalana de Medicina Familiar i Comunitària" "autores" => array:3 [ 0 => array:2 [ "Iniciales" => "R" "apellidos" => "Aragonès Forès" ] 1 => array:2 [ "Iniciales" => "P" "apellidos" => "Orozco López" ] 2 => array:2 [ "nombre" => "Grupo de Osteoporosis de la Societat Catalana de Medicina" "apellidos" => "Familiar i Comunitària" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13038155?idApp=UINPBA00004N" "url" => "/02126567/0000003000000006/v0_201607121033/13038155/v0_201607121034/es/main.assets" ] "itemAnterior" => array:15 [ "pii" => "13038153" "issn" => "02126567" "estado" => "S300" "fechaPublicacion" => "2002-10-15" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Aten Primaria. 2002;30:348-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3574 "formatos" => array:3 [ "EPUB" => 56 "HTML" => 3142 "PDF" => 376 ] ] "es" => array:9 [ "idiomaDefecto" => true "titulo" => "Comentario: Los medicamentos genéricos y algunos de los problemas para su implantación en España" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "348" "paginaFinal" => "349" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Commentary: Problems with increasing the use of generic drugs in Spain" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R Azagra Ledesma, A Aguyé Batista" "autores" => array:2 [ 0 => array:2 [ "Iniciales" => "R" "apellidos" => "Azagra Ledesma" ] 1 => array:2 [ "Iniciales" => "A" "apellidos" => "Aguyé Batista" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13038153?idApp=UINPBA00004N" "url" => "/02126567/0000003000000006/v0_201607121033/13038153/v0_201607121034/es/main.assets" ] "asociados" => array:1 [ 0 => array:16 [ "pii" => "13038748" "issn" => "02126567" "estado" => "S300" "fechaPublicacion" => "2002-10-15" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Aten Primaria. 2002;30:343-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2780 "formatos" => array:3 [ "EPUB" => 50 "HTML" => 2330 "PDF" => 400 ] ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "Substitution of generics for brand medicines in primary care centers" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "343" "paginaFinal" => "347" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Sustitución de medicamentos de marca por genéricos en la consulta de atención primaria" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "S Casado Buendía, JK Sagardui Villamor, M Lacalle Rodríguez-Labajo" "autores" => array:3 [ 0 => array:2 [ "Iniciales" => "S" "apellidos" => "Casado Buendía" ] 1 => array:2 [ "Iniciales" => "JK" "apellidos" => "Sagardui Villamor" ] 2 => array:2 [ "Iniciales" => "M" "apellidos" => "Lacalle Rodríguez-Labajo" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:8 [ "pii" => "13038151" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13038151?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13038748?idApp=UINPBA00004N" "url" => "/02126567/0000003000000006/v0_201607121033/13038748/v0_201607121034/en/main.assets" ] ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "Commentary: Problems with increasing the use of generic drugs in Spain" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "348" "paginaFinal" => "349" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "R Azagra Ledesma, A Aguyé Batista" "autores" => array:2 [ 0 => array:3 [ "Iniciales" => "R" "apellidos" => "Azagra Ledesma" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:3 [ "Iniciales" => "A" "apellidos" => "Aguyé Batista" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Family Physician and Specialist in Clinical Pharmacology. Co-director, Master´s Program in Primary Health Care and Associate Professor, Autonomous University of Barcelona. Badia del Vallès Primary Care Center, Barcelona, Spain." "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "Specialist in Family and Community Medicine, Ripollet Primary Care Center, Barcelona, Spain." "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Comentario: Los medicamentos genéricos y algunos de los problemas para su implantación en España" ] ] "textoCompleto" => "<hr></hr><p class="elsevierStylePara"><img src="27v30n06-13038749tab01.gif"></img></p><p class="elsevierStylePara">The interesting article in this issue by Casado Buendía and colleagues begins by recalling the novelty, in the Spanish market, of generic drugs, and by describing legislative developments in detail. These new measures are aimed at favoring the use of generic drugs, and naturally, at containing public expenditure in the pharmacies. However, the study draws attention to another novel characteristic of the generic drug market in Spain, which has been little covered in the media and rarely analyzed by physicians and pharmacists: the degree to which the citizen-user-patient actually accepts generic prescriptions, and the rate of substitution of brand-name products for generic ones. The study was designed to determine the degree of acceptance by users after they had received correct information about their health problem and about the characteristics of the medication recommended and prescribed through the public health system. This is what we now know as informed consent.</p><p class="elsevierStylePara">Generic drugs have been on the Spanish market for a bit longer than 5 years.<span class="elsevierStyleSup">1</span> The availability of generics was followed by the establishment of reference prices for groups of pharmaceuticals. Each group listing must contain at least one generic, members must be bioequivalent, and must be identified with the initials «EQ»<span class="elsevierStyleSup">2</span>. These structural changes were preceded by the elimination of public financing (the negative lists) for more than 1500 pharmaceutical products. These exclusions, undertaken by both the Spanish Socialist Workers Party in 1993 and by the Popular Party in 1997, were based on the need to contain health costs for medications, and were supported by expert commission documents such as the 1991 Abril-Matorell Report and the 1993 Report on Qualitative Indicators,<span class="elsevierStyleSup">3</span> which classified all medications available in the Spanish market according to potential quality or known therapeutic value. Current analyses based on evidence-based medicine establish different recommendations for each pharmaceutical on the basis of the quality of the scientific evidence.</p><p class="elsevierStylePara">These measures, requested by professional organizations<span class="elsevierStyleSup">4</span> and by Parliament, were put in place when politicians (as in Germany, The Netherlands, Denmark, Sweden and Norway) became convinced that the provisional cost containment measures taken by the Ministry of Health and Consumer Affairs (MHCA) by negotiating pacts with the College of Pharmacists and Farmaindustria, the organism that represents pharmaceutical firms in Spain (ie, a return of 0.7% to 1.6% on their investment), were insufficient, and that real costs were continuing to rise yearly at a rate greater than the gross national product.</p><p class="elsevierStylePara">These regulations and structural measures were aimed at modifying the supply of generics and reducing the cost of brand-name products by introducing another novelty: the possibility of copayment (the patient pays part of the total price of the product if he or she prefers a brand name that costs more than the reference price), or substitution, under certain circumstances, upon dispensation in the pharmacy. To favor cooperation by pharmacists, an increase in their profit margin for generics from 27.9% to 33% was agreed. In contrast to increasing the fixed profit margin, which is the same for all pharmacies in the country, a different approach was used for prescribing physicians in some autonomous communities, and in certain cases. Incentives and specific interventions were proposed to favor generic prescribing, with specific goals negotiated through service contracts with the National Institute of Health (INSALUD), or through specific agreements such as that negotiated with pharmacists in Catalonia.<span class="elsevierStyleSup">5</span> To favor cooperation by patients, the MHCA and autonomous communities developed a public information campaign to run for just over 20 days, at a cost of over 330 million pesetas (about 2 million euros).</p><p class="elsevierStylePara">One of the collateral effects of the new measures was to foment an increase in irrational dispensing at pharmacies, a result that merits a brief commentary for the purposes of stimulating debate. The most common practice is the use of a credit system in which, upon purchasing a given generic product, the buyer is given, at no extra cost, medications and other health care products whose total worth is, in some cases, more than the cost of the prescription being filled. As a result, many pharmacists fill prescriptions with a product made by a manufacturer that offers additional free products instead of the generic specified in the patient´s prescription: a practice known as substitution. This confuses the consumer because of constant changes that lead to no direct benefit, and because of apathy on the part of physicians who prefer one brand over another. The INSALUD has issued several warnings, noting that substitution of one generic for another should be the exception rather than the rule. In June 2001, the General Directorate of Pharmacy reprimanded Farmaindustria a second time for encouraging the credit system in pharmacies that dispense generics covered by the national health system.</p><p class="elsevierStylePara">The market for generics has leveled off, and now represents 5%-6% of all pharmaceutical costs to the national health system. This has disappointed professional groups with a stake in generics, the MHCA, and the manufacturers of generics. The MHCA has expressed its apparent satisfaction over the fact that pharmaceutical costs rose by less than 10% per year during 2000 and 2001, as a result of price decreases by brand-name companies to comply with the reference prices. But an analysis of costs during the first part of 2002 has set alarm bells ringing: in comparison to 2001, increases have averaged between 12% and 13% nationwide, with some autonomous communities reporting increases of more than 16%.</p><p class="elsevierStylePara">From the viewpoint of prescribing physicians, the policy of incentives should be broadened and deepened. This will be necessary to generate a culture of change in deeply-rooted habits. In addition, prescribing physicians have been pleading for the administration to lay aside its permissiveness and clamp down on instances of noncompliance with current regulations on substitute dispensing in pharmacies.<span class="elsevierStyleSup">6</span> Out of respect for colleagues who contribute their expertise to these advisory groups, an analysis of the problems surrounding indications and prescribing practices, and proposals for improvement, should not be left exclusively in the hands of experts in pharmaceutical dispensation.</p><p class="elsevierStylePara">As the study by Casado Buendía and colleagues shows, quite a large proportion of patients agreed to switch from a brand-name product to a generic after they had received appropriate information. Their decision rarely led to unease on the patient´s part or apprehension on the physician´s. This study supports the favorable impressions<br></br> obtained in surveys undertaken by the MHCA and autonomous communities, and in reports to the Spanish Congress and Economic and Social Council.</p><p class="elsevierStylePara">In summary, patients who understand and cooperate with generic prescribing once they have been adequately informed are to be commended. However, poor marks go to health authorities responsible for developing regulatory measures who use provisional, primarily economic interventions that do not emphasize or follow on from earlier, successful initiatives to create incentives for the generics market measures which have been shown to be effective and efficient.<span class="elsevierStyleSup">6</span> The provisional measures do not go to the heart of the problem, when the facts are that more than half of the annual growth in pharmaceutical costs is due to the introduction of new and more expensive drugs, and that experts continue to recommend the entry of such new products in the market. We encourage the new minister of Health and Consumer Affairs to attend to the essence of measures set down in the legislation in effect since 2000<span class="elsevierStyleSup">2</span> that regulates reference prices.</p>" "pdfFichero" => "27v30n06a13038749pdf001.pdf" "tienePdf" => true "multimedia" => array:2 [ 0 => array:6 [ "identificador" => "tbl1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tablaImagen" => array:1 [ 0 => array:4 [ "imagenFichero" => "27v30n06-13038749tab01.gif" "imagenAlto" => 388 "imagenAncho" => 359 "imagenTamanyo" => 14930 ] ] ] ] ] ] 1 => array:5 [ "identificador" => "tbl2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:6 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "referenciaCompleta" => "Modificación de la Ley 25/1990 de 20 de diciembre, del Medicamento. BOE n.º 315, de 31 de diciembre de 1996." "contribucion" => array:1 [ 0 => array:1 [ "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Ley 13/1996 de 30 de Diciembr.e" 1 => "de Medidas Fiscale.s" 2 => "Administrativas y de Orden Social." ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "referenciaCompleta" => "BOE n.º 154, de 29 de junio de 1999." "contribucion" => array:1 [ 0 => array:1 [ "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Real Decreto 1035/99" 1 => "de 18 de juni.o" 2 => "por el que se regula el sistema de precios de referencia en el financiamiento público de medicamentos." ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "referenciaCompleta" => "Informe sobre indicadores cualitativos de la prescripción de medicamentos. Subdirección General de Prestaciones y Evaluación de Tecnologías Sanitarias. Madrid: Ministerio de Sanidad y Consumo, 1994." "contribucion" => array:1 [ 0 => array:1 [ "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Del Río A" 1 => "Guerra L" 2 => "por el Comité de Expertos." ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "¿Podemos contener el gasto en farmacia? Atención Primaria 1993;11:117-8." "contribucion" => array:1 [ 0 => array:3 [ "titulo" => "¿Podemos contener el gasto en farmacia?" "idioma" => "es" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Azagra Ledesma R." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Atención Primaria" "fecha" => "1993" "volumen" => "11" "paginaInicial" => "117" "paginaFinal" => "8" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8453001" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "referenciaCompleta" => "Pacto de prescripción farmacéutica del Institut Català de la Salut. En: Nin Julve E, editor. Manual de gestión de la prescripción farmacéutica en atención primaria. Madrid: Sociedad Española de Directivos de Atención Primaria, 2001; p. 289-99." "contribucion" => array:1 [ 0 => array:1 [ "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Catalán Ramos A" 1 => "Gené Badia J." ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "referenciaCompleta" => "Consenso sobre atención farmacéutica. Madrid: Dirección General de Farmacia y Productos Sanitarios, 2001. Disponible en: http://www.msc.es/farmacia/consenso_af/homeconsenso.htm." "contribucion" => array:1 [ 0 => array:1 [ "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Anónimo." ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/02126567/0000003000000006/v0_201607121033/13038749/v0_201607121034/en/main.assets" "Apartado" => array:4 [ "identificador" => "14695" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Originales" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/02126567/0000003000000006/v0_201607121033/13038749/v0_201607121034/en/27v30n06a13038749pdf001.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13038749?idApp=UINPBA00004N" ]
Article information
ISSN: 02126567Original language: English
The statistics are updated each day
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 1 | 0 | 1 |
| 2024 October | 17 | 1 | 18 |
| 2024 September | 27 | 4 | 31 |
| 2024 August | 31 | 12 | 43 |
| 2024 July | 27 | 10 | 37 |
| 2024 June | 22 | 5 | 27 |
| 2024 May | 24 | 12 | 36 |
| 2024 April | 29 | 2 | 31 |
| 2024 March | 37 | 5 | 42 |
| 2024 February | 47 | 8 | 55 |
| 2024 January | 53 | 10 | 63 |
| 2023 December | 25 | 4 | 29 |
| 2023 November | 31 | 7 | 38 |
| 2023 October | 56 | 9 | 65 |
| 2023 September | 50 | 7 | 57 |
| 2023 August | 75 | 5 | 80 |
| 2023 July | 35 | 8 | 43 |
| 2023 June | 26 | 8 | 34 |
| 2023 May | 29 | 6 | 35 |
| 2023 April | 19 | 2 | 21 |
| 2023 March | 30 | 5 | 35 |
| 2023 February | 21 | 3 | 24 |
| 2023 January | 38 | 5 | 43 |
| 2022 December | 37 | 10 | 47 |
| 2022 November | 49 | 3 | 52 |
| 2022 October | 42 | 8 | 50 |
| 2022 September | 38 | 7 | 45 |
| 2022 August | 43 | 9 | 52 |
| 2022 July | 42 | 13 | 55 |
| 2022 June | 12 | 6 | 18 |
| 2022 May | 17 | 10 | 27 |
| 2022 April | 39 | 10 | 49 |
| 2022 March | 36 | 13 | 49 |
| 2022 February | 19 | 7 | 26 |
| 2022 January | 15 | 7 | 22 |
| 2021 December | 21 | 12 | 33 |
| 2021 November | 21 | 14 | 35 |
| 2021 October | 25 | 10 | 35 |
| 2021 September | 13 | 18 | 31 |
| 2021 August | 9 | 6 | 15 |
| 2021 July | 12 | 12 | 24 |
| 2021 June | 18 | 10 | 28 |
| 2021 May | 17 | 4 | 21 |
| 2021 April | 34 | 42 | 76 |
| 2021 March | 25 | 15 | 40 |
| 2021 February | 24 | 7 | 31 |
| 2021 January | 15 | 7 | 22 |
| 2020 December | 18 | 15 | 33 |
| 2020 November | 12 | 8 | 20 |
| 2020 October | 12 | 6 | 18 |
| 2020 September | 14 | 21 | 35 |
| 2020 August | 14 | 28 | 42 |
| 2020 July | 19 | 13 | 32 |
| 2020 June | 13 | 12 | 25 |
| 2020 May | 17 | 9 | 26 |
| 2020 April | 8 | 12 | 20 |
| 2020 March | 14 | 8 | 22 |
| 2020 February | 15 | 12 | 27 |
| 2020 January | 12 | 7 | 19 |
| 2019 December | 39 | 5 | 44 |
| 2019 November | 9 | 7 | 16 |
| 2019 October | 4 | 1 | 5 |
| 2019 September | 9 | 3 | 12 |
| 2019 August | 7 | 3 | 10 |
| 2019 July | 8 | 11 | 19 |
| 2019 June | 37 | 19 | 56 |
| 2019 May | 134 | 26 | 160 |
| 2019 April | 34 | 8 | 42 |
| 2019 March | 11 | 6 | 17 |
| 2019 February | 9 | 14 | 23 |
| 2019 January | 8 | 8 | 16 |
| 2018 December | 6 | 9 | 15 |
| 2018 November | 9 | 7 | 16 |
| 2018 October | 10 | 13 | 23 |
| 2018 September | 2 | 4 | 6 |
| 2018 August | 7 | 0 | 7 |
| 2018 July | 5 | 1 | 6 |
| 2018 June | 8 | 2 | 10 |
| 2018 May | 1 | 2 | 3 |
| 2018 April | 6 | 0 | 6 |
| 2018 March | 1 | 0 | 1 |
| 2018 February | 3 | 1 | 4 |
| 2018 January | 5 | 0 | 5 |
| 2017 December | 1 | 1 | 2 |
| 2017 November | 2 | 1 | 3 |
| 2017 October | 4 | 4 | 8 |
| 2017 September | 6 | 1 | 7 |
| 2017 August | 7 | 3 | 10 |
| 2017 July | 11 | 3 | 14 |
| 2017 June | 10 | 3 | 13 |
| 2017 May | 18 | 3 | 21 |
| 2017 April | 11 | 9 | 20 |
| 2017 March | 14 | 20 | 34 |
| 2017 February | 24 | 2 | 26 |
| 2017 January | 9 | 1 | 10 |
| 2016 December | 12 | 2 | 14 |
| 2016 November | 16 | 2 | 18 |
| 2016 October | 29 | 2 | 31 |
| 2016 September | 22 | 1 | 23 |
| 2016 August | 17 | 2 | 19 |
| 2016 July | 19 | 6 | 25 |
| 2016 June | 34 | 10 | 44 |
| 2016 May | 16 | 4 | 20 |
| 2016 April | 14 | 1 | 15 |
| 2016 March | 8 | 3 | 11 |
| 2016 February | 15 | 3 | 18 |
| 2016 January | 7 | 0 | 7 |
| 2015 December | 12 | 2 | 14 |
| 2015 November | 18 | 0 | 18 |
| 2015 October | 16 | 3 | 19 |
| 2015 September | 20 | 5 | 25 |
| 2015 August | 7 | 1 | 8 |
| 2015 July | 11 | 2 | 13 |
| 2015 June | 5 | 2 | 7 |
| 2015 May | 8 | 3 | 11 |
| 2015 April | 8 | 11 | 19 |
| 2015 March | 9 | 2 | 11 |
| 2015 February | 7 | 2 | 9 |
| 2015 January | 19 | 0 | 19 |
| 2014 December | 24 | 4 | 28 |
| 2014 November | 15 | 0 | 15 |
| 2014 October | 31 | 2 | 33 |
| 2014 September | 23 | 0 | 23 |
| 2014 August | 17 | 3 | 20 |
| 2014 July | 25 | 0 | 25 |
| 2014 June | 44 | 1 | 45 |
| 2014 May | 11 | 1 | 12 |
| 2014 April | 16 | 1 | 17 |
| 2014 March | 10 | 2 | 12 |
| 2014 February | 11 | 1 | 12 |
| 2014 January | 18 | 1 | 19 |
| 2013 December | 18 | 3 | 21 |
| 2013 November | 12 | 2 | 14 |
| 2013 October | 29 | 2 | 31 |
| 2013 September | 16 | 1 | 17 |
| 2013 August | 22 | 3 | 25 |
| 2013 July | 16 | 1 | 17 |
| 2002 October | 401 | 0 | 401 |
Show all
